Investment
Features
FeesSafety
Academy
More
Pluang+

Compare INNIO N.V. Ordinary Shares (INIO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

INNIO N.V. Ordinary SharesTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

INNIO N.V. Ordinary Shares vs Inovio Pharmaceuticals Inc — how do they compare? INNIO N.V. Ordinary Shares trades at $16 (market cap $13.73B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $103.19M). The key difference: INNIO N.V. Ordinary Shares is far larger — about 133.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

INIOINO
Market Cap
$13.73B$103.19M
Volume
5,012,1958,461,580
Sector
IndustrialsHealth
52-Week High
$41.13$2.60
52-Week Low
$16.50$0.66
Typical Hold Time
0 Days43 Days
Enterprise Value
$15.39B$74.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

INNIO N.V. Ordinary Shares

No Aura AI signal available yet.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.

INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INIO
100% Buy0% Sell
Avg holding period · 0 Days
INO
97% Buy3% Sell
Avg holding period · 43 Days

About INNIO N.V. Ordinary Shares

INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.

Read more on INIO →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →